These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29704066)

  • 21. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early recurrence risk: aromatase inhibitors versus tamoxifen.
    Bria E; Carlini P; Cuppone F; Vaccaro V; Milella M; Cognetti F
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1239-53. PubMed ID: 20735310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Petrelli F; Cavallone M; Dottorini L
    Eur J Cancer; 2023 Nov; 193():113322. PubMed ID: 37769477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
    van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
    Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
    Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
    Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
    Snoj N; Paridaens R; Cufer T
    Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent perspectives of endocrine therapy for breast cancer.
    Utsumi T; Kobayashi N; Hanada H
    Breast Cancer; 2007; 14(2):194-9. PubMed ID: 17485906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT; Carlson RW
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
    Pennery E
    Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How do I recommend extended adjuvant hormonal therapy?
    Mehta A; Carpenter JT
    Curr Treat Options Oncol; 2014 Mar; 15(1):55-62. PubMed ID: 24338340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
    Zdenkowski N; Forbes JF; Boyle FM; Kannourakis G; Gill PG; Bayliss E; Saunders C; Della-Fiorentina S; Kling N; Campbell I; Mann GB; Coates AS; Gebski V; Davies L; Thornton R; Reaby L; Cuzick J; Green M;
    Ann Oncol; 2016 May; 27(5):806-12. PubMed ID: 26861603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    Aapro M; van de Velde CJ; Markopoulos C; Bartlett JM; Putter H; Coleman RE
    Breast; 2013 Aug; 22(4):488-94. PubMed ID: 23454040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
    Hayes DF
    Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.